Skip directly to content



150 HIV Organizations Urge Continuation of D:A:D Study
February 20, 2015 – HIV drugs are used in combinations, so it is right that the companies who make and sell these drugs collaborate on this study on long-term safety.

Governor Cuomo’s Ending the Epidemic Task Force Completes Plan to End AIDS in NY State by 2020
– Activists, service providers, public health professionals hail governor’s leadership, call on legislators and local governments to join forces to end the epidemic –
Albany, New York – January 13, 2015.  Today the Ending the Epidemic Task Force, convened by the New York State Department of Health (DOH) at the behest of Governor Andrew M. Cuomo, completed its comprehensive, rigorous, and unprecedented Plan to End AIDS in New York State by 2020.

Advocates Urge Governor Cuomo to Withdraw Mandatory Quarantine Order
October 26, 2014 – We write as professionals, activists, and public health researchers who have worked to combat AIDS and other infectious diseases in New York and around the world for over three decades.  We have not forgotten how HIV/AIDS was at first largely ignored while it appeared to affect only marginalized communities or the stigma generated once fear of the virus took hold in the larger population.  We have watched with growing concern as Ebola virus disease (EVD) was ignored far too long while confined to some of the poorest countries in the world, and how it has now led to hysteria here in the United States, based on only a very small number of cases. As you know, stigma remains our biggest enemy in fighting AIDS and could quickly become the biggest barrier in combatting EVD.  Therefore, we implore you to withdraw the mandatory quarantine requirement for all people entering the United States through Newark Liberty International Airport and John F. Kennedy International Airport who have had direct contact with individuals with EVD in Guinea, Liberia, and Sierra Leone.

NYS Ending Epidemic Task Force
New York, New York – October 14, 2014. Treatment Action Group (TAG) welcomes today’s announcement by the New York State Department of Health (DOH) of the Ending the Epidemic Task Force to more fully develop Governor Andrew Cuomo’s Plan to End AIDS as an epidemic in New York State by the year 2020.

Letters to Menigitis Vaccine Makers Urging Efficacy Studies in People with HIV
September 17, 2014 – Significant gaps in our knowledge base on the effectiveness of meningococcal vaccination with respect to preventing disease in people living with HIV make it more difficult to mount a strategic public health response to the outbreaks, both in New York City and other settings.

2014 Pipeline Report
July 20, 2014 – HIV, HCV, and TB Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development.
Read the HIV chapters online:

Treatment Action Group Commends Governor Cuomo for Launching Historic New York State Plan to End AIDS
TAG Calls on Governor to Expeditiously Appoint a High-Level Task Force to Develop Blueprint to End AIDS Deaths and Halt New HIV Infections

June 29, 2014, New York, New York – Treatment Action Group (TAG) applauds Governor Andrew M. Cuomo for his full support of a historic community-developed plan to end the AIDS epidemic in New York State by 2020, as announced this morning by the Governor’s office and reported in today’s edition of the New York Times (“Cuomo Plan Seeks to End New York’s AIDS Epidemic,” Anemona Hartocollis, page A18). With this bold initiative, New York State—long the epicenter of the nation’s HIV epidemic—becomes the first jurisdiction anywhere in the world to publicly declare a goal of ending AIDS as an epidemic with the launch of a comprehensive effort to end AIDS deaths and halt new infections by employing state-of-the-art testing, preventive technologies, treatment, and supportive services.

ACT UP to Tom Frieden: You’re MIA on HIV
New Infections on the Rise in Key Subpopulations, Despite Options for Prevention
June 9, 2014 – Members of ACT UP NY, along with Treatment Action Group (TAG) and Atlanta allies, will meet with the Centers for Disease Control & Prevention (CDC)’s HIV prevention personnel in Atlanta, GA. ACT UP will call upon the CDC to meet its commitment of keeping all Americans healthy and to act now upon the promise of TasP, PrEP, and PEP, address social and structural barriers to lifesaving prevention options, and reduce the transmission of HIV in those groups where the incidence is rising.

Research Toward a Cure
March 27, 2014 – A listing of clinical trials and observational studies related to the research effort to cure HIV infection, mainly derived from the online registry. Click the identifier numbers for a link to the full entry containing detailed information on the trial design, enrollment criteria, principal investigators and location(s). It's important to appreciate that at the current time, none of these studies is expected to produce a cure for HIV infection—they represent research working toward that goal. Table 3 contains completed studies, with links to published or presented results where available.

Filling the Gaps in the U.S. HIV Treatment Cascade: Developing a Community-Driven Research Agenda
December 1, 2013 – TAG and amfAR sponsored a workshop in Washington, D.C., on June 18–19, 2013, to develop a community-based agenda to improve implementation of effective service-delivery approaches and identify research priorities for improved management of HIV treatment and prevention, with a particular focus on filling the gaps in the United States HIV continuum of care (or treatment cascade). This document represents the outcomes from that meeting, attended by representatives from government, academia, and health care systems, along with community-based advocates and service providers.

167 Organizations and 513 Individuals Signed on to Letter to Secretary Sebelius on the Allowance of Co-pay Assistance in the ACA Health Plans
December 2, 2013 – We, the undersigned organizations and individuals, are writing to urge that the HHS issue clear guidance on the allowance of drug industry–provided co-payment, co-insurance, or other out-of-pocket discount cards and coupons in the Affordable Care Act’s (ACA) Health Insurance Marketplaces. As people living with, and organizations serving people with, HIV, HCV, and other life-threatening and chronic health conditions, we are alarmed by the possibility of the prohibition of these critical financial lifelines in the ACA, just as affordable health insurance for people with preexisting conditions is finally becoming a reality in the United States, thanks to the ACA.

amfAR/TAG Issue Brief: The Cost of Flat Funding for Biomedical Research
August 12, 2013 – “The Costs of Flat Funding for Biomedical Research,” prepared by the Foundation for AIDS Research (amfAR) in collaboration with TAG, examines the declining purchasing value of public funding for health research at the National Institutes of Health (NIH) and the impact this has on public health, scientific progress, US productivity, and US science leadership.

2013 Pipeline Report
June 30, 2013 – HIV, HCV, and TB Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development

Preexposure Prophylaxis (PrEP) Trial among Thai Injection Drug Users Marred by Lack of Response to Community Concerns
June 26, 2013 – On June 12, results from an efficacy trial of tenofovir as pre-exposure prophylaxis (PrEP) against HIV infection in individuals with a self-reported history of injection drug use were published in the Lancet. The trial was sponsored by the U.S. Centers for Disease Control and Prevention (CDC) and took place in Bangkok, Thailand (named the Bangkok Tenofovir Study). The publication was accompanied by a flurry of press releases and drew considerable news coverage due to the documentation of a statistically significant reduction in risk of HIV acquisition of 48.9%.

Letter to Gilead - Tenefovir Alafenamide Fumarate (TAF) (Final with 293 signatories)
June 24, 2013 – With a phase II clinical trial of tenofovir alafenamide fumarate (TAF) yielding encouraging preliminary results and regulatory planning for TAF-inclusive fixed-dose combinations (FDCs) under way, we are compelled to reach out to you regarding the need for a stand-alone formulation of the drug.

The Immune System, HIV, and Aging
June 3, 2013 – Little more than a decade ago, it was almost inconceivable that the issue of aging with HIV infection would emerge as an important concern. But it has now become clear that combination antiretroviral therapy (ART) can suppress virus replication for many years—likely for life—in most people who can access the drugs, and the opportunistic infections that were once the primary causes of illness have largely evanesced everywhere treatment is available. Morbidity and mortality from HIV infection has plummeted, and the survival of HIV-positive individuals is edging ever closer to that of comparable HIV-negative people. With the specter of AIDS having finally been chased from the near horizon, attention has turned to health problems that may lie further down the road.

Revitalizing the U.S. National HIV/AIDS Strategy
Meeting Report and Action Plan
April 15, 2013 – On December 11–12, 2012, in Washington, D.C., Treatment Action Group (TAG) hosted a meeting of HIV advocates, service providers, and researchers from across the United States (U.S.) to review the current state of the national HIV response and discuss how to revitalize the National HIV/AIDS Strategy (NHAS). Meeting participants reviewed the latest data, discussed the changing landscape of the HIV response, and developed recommendations for continued and expedited progress. The Meeting Report summarizes the presentations and discussions, and outlines the key recommendations from participants. The Action Plan incorporates the recommendations from the meeting report.

Funding Scientific Innovation: Global Investments in HIV Treatment Research and Development in 2010 and 2011

March 6, 2013 – Advances in HIV treatment research in 2010 and 2011 saw improvement in treatment regimens and strategies, and reinvigorated optimism for finding a cure. In 2012, TAG and AVAC, with financial support from UNAIDS, put forth a collaborative effort to analyze investment trends in HIV treatment research and development (R&D) in 2010 and 2011.

Micardis Sign-On Letter to Boehringer Ingelheim
November 30, 2012 – Dear Dr. Piliero: We, the undersigned organizations and individuals, urge Boehringer Ingelheim Pharmaceuticals to reconsider its negative decision to provide free telmisartan (Micardis) and matching placebo to the AIDS Clinical Trials Group so that it may move forward with Study A5317, a multicenter trial evaluating the effects of telmisartan on fibrotic and inflammatory contributors to end-organ disease in HIV-infected patients well controlled on antiretroviral therapy.

2012 Pipeline Report

HIV, Hepatitis C Virus (HCV), and Tuberculosis (TB) Drugs, Diagnostics, Vaccines, and Preventive Technologies in Development

July 22, 2012 – Visit our new website to:

  • Read the report online
  • Download individual chapters as PDFs
  • Browse for specific information by agent

Letter Opposing a Proposed Low-Dose Stavudine Trial
December 14, 2011
Dear Mr. and Mrs. Gates, We write as people with HIV and community activists with serious and unresolved concerns about the proposed clinical trial comparing stavudine at 20 mg to tenofovir. Although we are broadly very supportive of dose optimisation strategies, we do not support this trial; we do not think that the Bill and Melinda Gates Foundation should support it; nor do we think it should proceed. Several of us have discussed this with your representatives both formally and informally over the past months. Those of us who met with your representatives on 19 July 2011 at the International AIDS Society conference in Rome received no response to the concerns we raised. We summarise our objections as follows:

HIV Cure-Related Research Workshop Report 

October 2011 – The meeting, sponsored by the AIDS Policy Project, amfAR, Project Inform, and TAG, featured an overview of HIV latency, persistence, and eradication research; lessons from past clinical trials; a review of current or impending trials; and a full discussion of issues including trial design, appropriate markers and endpoints, and development of better assays. Participants heard a presentation on the ethics of clinical trials and discussed the federal regulatory process and how best to engage the several branches of the U.S. Food and Drug Administration (FDA) in a coordinated and collaborative way to work together to ensure that cure-related clinical trials proceed expeditiously, ethically, and safely.

2011 Pipeline Report – Second Edition

HIV, Hepatitis C Virus (HCV), and Tuberculosis Drugs, Diagnostics, Vaccines, and Preventive Technologies in Development

September 2011 – As this i-Base and TAG 2011 Pipeline Report, Second Edition, makes clear, medically, the prospect for people with HIV, hepatitis C virus (HCV), and tuberculosis (TB) to live long and healthy lives—and in the cases of HCV and TB, to be cured rapidly with safe, effective, oral combination therapy—has never been better.

An Exploratory Analysis of HIV Treatment Research and Development Investments in 2009

July 2011 – The HIV treatment research landscape is changing. Thanks to recent treatment scale-up and prevention science breakthroughs and the new global treatment target of 15 million by 2015, there is real momentum to bring the epidemic under control and ultimately end it. To capitalize on these scientific gains, continued investment and innovation are necessary to prevent new infections, to ensure people currently on treatment are able to continue, and to scale up treatment to reach all those who will benefit from earlier initiation of antiretroviral therapy. This report from TAG, UNAIDS, and the AIDS Vaccine Advocacy Coalition documents $2.46 billion in HIV-related research investments.